Mirena (Levonorgestrel)

Levonorgestrel, the active ingredient in Mirena, is a progestin presented as a 52 mg intrauterine system for intrauterine use. It prevents pregnancy and can be used to manage heavy menstrual bleeding in women of reproductive age.

GNH USA supplies Mirena as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirena, a levonorgestrel intrauterine system, is employed within hormonal contraceptive and menstrual‑management pathways.

Contraception: provides highly effective, reversible birth control for up to five years. Heavy menstrual bleeding: reduces menstrual blood loss and improves anemia associated with excessive bleeding. Endometrial hyperplasia (non‑cancerous): suppresses endometrial proliferation in selected cases.

Adverse reactions to Mirena are reported across a spectrum of frequencies.

Common Side Effects: - Irregular vaginal bleeding or spotting - Amenorrhea (absence of periods) - Pelvic or cramping pain after insertion - Hormonal changes such as acne or breast tenderness

Serious or Rare Side Effects: - Uterine perforation during insertion - Expulsion of the device - Pelvic inflammatory infection - Ectopic pregnancy if conception occurs after expulsion

Before prescribing Mirena, clinicians should consider several precautionary measures.

Pregnancy screening: confirm the patient is not pregnant prior to insertion. Contraindications: avoid use in active pelvic infection, uterine anomalies, or known/suspected malignancy. Follow‑up examination: schedule a pelvic check 4–6 weeks after insertion to verify placement. Signs of expulsion: educate patients to report unexpected vaginal discharge or feeling of device. Interaction with hormonal therapies: assess concurrent use of other hormonal contraceptives. Store at ambient temperature: keep the device below 25 °C in its original packaging, protected from moisture and direct sunlight.

Levonorgestrel released from Mirena may have pharmacokinetic interactions with certain medicines.

Major Interactions (Avoid): - Rifampin and other strong enzyme inducers (e.g., carbamazepine, phenytoin, St. John’s wort) may reduce levonorgestrel levels. - Antiretroviral efavirenz can lower hormonal efficacy. - Antifungal ketoconazole (strong CYP3A4 inhibitor) may increase systemic exposure.

Moderate Interactions (Monitor Closely): - Certain antibiotics (e.g., tetracycline) have limited effect but should be noted. - Hormonal therapies such as combined oral contraceptives may alter bleeding patterns. - Herbal supplements containing phytoestrogens may require monitoring.